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Fig. 1. Lower plasma concentrations of ribavirin were related to the higher
number of ‘‘unfavorable’’ CNT2 SNPs (rs11854484 [TT], rs2413775 [AT/TT] and
rs1060896 [CC]). Only the difference between group ‘‘0’’ and ‘‘3’’ is statistically
signiﬁcant (p = 0.006).
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use of TDM to adjust the drug exposure both to enhance efﬁcacy
and reduce toxicity (p <0.001) [9,10].
We therefore have no clear answer to the question as to
whether genetic SLC28 transporter polymorphisms predict
ribavirin plasma levels. If RBV plasma exposure maintains its
clinical impact in new anti-HCV treatment studies comparative
evaluations of pharmacogenetics vs. early pharmacokinetics are
warranted. It should also be highlighted that the cost of a single
early (2 weeks) determination of ribavirin plasma concentration
does not signiﬁcantly impact on the overall expenditure associ-
ated with the use of (triple) anti-HCV therapy and may well con-
tribute to a fruitful tailored management.
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manuscript.Reply to: ‘‘Estimating ribavirin plasma exposure: Genetics or
therapeutic drug monitoring?’’reported in our study [1]. Since our study included patients with
a different RBV dosage, drug serum levels were adjusted to dos-
age. To address this issue in the study design, we analyzed only
RBV serum levels at weeks 4 and 8 before eventual dose modiﬁ-
cation. As an alternative approach to account for drug dose
adjustment in pharmacokinetic studies, D’Avolio et al. adjusted
RBV concentrations for the dose pro kilogram and for dose reduc-
tion in their HCV positive patients. Although their ﬁndings did
not exactly replicate the results of our study, the described
association between lower RBV plasma concentrations and a
combination of ‘‘unfavorable’’ CNT2 SNPs must be taken asTo the Editor:
We thank Dr. D’Avolio and colleagues for their critical comment
on the measurement of ribavirin (RBV) plasma concentration
during HCV therapy in general and its genetic basis in particular.
This contribution adds further insight into the genetic basis of
RBV bioavailability, which has been described in our study [1].
In their letter to the editor, D’Avolio et al. described an association
between lower RBV plasma concentrations and a combination of
‘‘unfavorable’’ CNT2 SNPs (rs11854484, rs2413775, rs1060896) in
186 HCV patients. Interestingly, an association between RBV
plasma concentrations and rs11854484 alone was not seen as13 vol. 59 j 631–640
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morphisms for RBV bioavailability and related clinical outcomes.
We agree that these genetic associations in heterogeneous stud-
ies with a limited patient number need further replication to
strengthen the importance of the investigated SNPs.
Interestingly, our colleagues observed that RBV concentra-
tions at week 2 have a predicting value for RBV concentrations
at week 4. Therefore, early RBV serum measurement could help
precocious adjustment of RBV dosage in HCV therapy. Most
recent trials with direct-acting antiviral drugs indicate a
continuous role of RBV in antiviral therapy regimens and further
studies will clearly contribute to optimize RBV dosage. For rou-
tine clinical practice, comparative evaluations of pharmacogenet-
ics versus early pharmacokinetics are rather dispensable in our
opinion as drug level measurement will remain the key for clin-
ical decision-making today. However, genetic studies like ours
and the one of D’Avolio et al. contribute to the molecular under-
standing of pharmacokinetics and may guide the way towards a
personalized HCV treatment strategy in the future.‘‘Wait and see’’ policy for early hepatocellular carcinomaJournal of Hepatology 201Conﬂict of interest
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JOURNAL OF HEPATOLOGYTo the Editor:
We would like to comment on the recent article by Midorikawa
and colleagues [1] about the management of early hepatocellular
carcinoma (HCC). The authors suggest a ‘‘wait and see’’ policy
when these lesions are recognized in a cirrhotic liver since the
difference between the beneﬁt of resection and observation was
negligible in this subgroup of patients. In the authors’ opinion,
only overt HCC should be promptly treated whereas early HCC
lesions should not be submitted to any form of therapy (including
liver resection and percutaneous ablation) because of the treat-
ment-related risks of liver function damage and severe complica-
tions. This clinical scenario parallels that of prostate cancer (PC):
as it happens for small HCC detected during surveillance pro-
grams, more and more small volume tumoral foci are detected
on prostatic biopsy ensuing Prostate Speciﬁc Antigen (PSA)
screening [2]. Nowadays, deferred treatment in patients with
insigniﬁcant disease has been advocated in the belief that radical
prostatectomy is associated with signiﬁcant morbidity and
decrease in the quality of life whereas the majority of men are
not at risk for dying of the disease, and that those who demon-
strate disease progression can be identiﬁed and treated before
the tumor becomes incurable [2]. As a consequence, over the last
decade, active surveillance programs have gained popularity: in
suitable candidates, stringent follow-up protocols including
repeat biopsy are implemented so as to pick-up early tumoral
progression [3]. However, similarities between HCC and PC clin-
ical scenarios end at this point: the two tumors have different
natural histories HCC carrying the worse prognosis and being
superimposed on a chronic disease, which per se affects both
patients’ outcome and the decision as to whether or not to start
a whatsoever form of treatment. This makes the window for cura-
tive therapy much narrower than in patients with PC. We agree
that surgery (including resection and liver transplantation) repre-
sents an undue and costly overtreatment for an early HCC, but
the same is not true for radiofrequency ablation (RFA). In our
opinion, the Midorikawa’s suggestion cannot be entirely sharedsince it relies on a misconception that surgery and local ablation
are equivalent in terms of complications rate and capability of
damaging liver function. To support their assumption they quote
outdated and questionable references. In particular, the authors
cite the article by Llovet et al. [4] where an exceedingly high rate
of neoplastic seeding after RFA was reported. Those results, how-
ever, have been harshly criticized and a subsequent multicenter
survey demonstrated clearly that, using a correct needle with-
drawal technique, the seeding rate was far lower (less than
0.9% out of 1314 patients) and negatively affected only by a pre-
vious biopsy on the treated HCC nodule [5]. The authors seem to
ignore that the worldwide use of RFA for HCC depends especially
on its high efﬁcacy in local control of the disease and lower inva-
siveness and costs when compared to surgery. In addition, there
is recent evidence that RFA and resection offer similar results in
terms of overall survival in case of HCC up to 3 cm emerging in
well compensated cirrhosis [6,7].
One more drawback of an attendant approach for early HCC is
that leaving a patients with an untreated cancer (even if small)
poses other kinds of problems. Back to the parallelism with PC,
the active surveillance is accepted by patients with reluctance
as it is demonstrated by the low rate of enrollment in such proto-
cols (not more than 30% of the suitable candidates) [2]. Several
reasons can explain this ﬁnding: the inability to predict with abso-
lute certainty favorable from unfavorable disease on an individual
basis, the poor predictive markers of progression, and ﬁnally the
difﬁculty of modifying the established standards of care. All these
factors, including the psychological attitude of patients and the
loss of the opportunity for cure during the surveillance period,
should be taken into account in case of an active surveillance
protocol for early HCC as suggested by Midorikawa et al.
It is not surprising that some urological groups are trying to
apply the concept of local ablation in low-risk PC patients [8].
Local therapy might prove to be the middle ground for this sub-
group of men, by combining acceptable cancer treatment with
low morbidity.3 vol. 59 j 631–640 635
